Saturday 31 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

466.16 5.43 +1.18%

Follow AMGN

Alert me

Market cap: $249.1B
P/E: 28.7×
Fwd P/E: 27.9×
Dividend yield: 2.13%
F-score: 7/9
Altman Z: 1.69
Beneish M: −2.27
Dividend safety: 56/100

Overview Business Profile Earnings & Analysis Segments Filings

Amgen Inc. (AMGN) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by regions, and margins
U.S.	26,419	71.89%
ROW	10,332	28.11%
Gross margin		67.25%
Operating margin		24.71%
Pre-tax margin		24.42%

Revenue by product or service $m

Line	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016
Other products	5,710 21.98%	5,374 21.14%	4,743 20.30%	5,572 23.46%	2,583 11.30%	3,158 13.74%
ENBREL	4,465 17.19%	4,996 19.65%	5,226 22.37%	5,014 21.11%	5,433 23.78%	5,965 25.94%
Prolia	3,248 12.50%	2,763 10.87%	2,672 11.44%	2,291 9.65%	1,968 8.61%	1,635 7.11%
Otezla	2,249 8.66%	2,195 8.63%	178 0.76%	0 0.00%	—	—
XGEVA	2,018 7.77%	1,899 7.47%	1,935 8.28%	1,786 7.52%	1,575 6.89%	1,529 6.65%
Other revenues	1,682 6.47%	1,184 4.66%	1,158 4.96%	1,214 5.11%	1,054 4.61%	1,099 4.78%
Aranesp	1,480 5.70%	1,568 6.17%	1,729 7.40%	1,877 7.90%	2,053 8.99%	2,093 9.10%
Repatha	1,117 4.30%	887 3.49%	661 2.83%	550 2.32%	—	—
KYPROLIS	1,108 4.26%	1,065 4.19%	1,044 4.47%	968 4.08%	835 3.65%	—
Nplate	1,027 3.95%	850 3.34%	795 3.40%	—	—	—
Vectibix	873 3.36%	—	—	—	—	—
EVENITY	530 2.04%	350 1.38%	—	—	—	—
BLINCYTO	472 1.82%	—	—	—	—	—
KRYSTEXXA	0 0.00%	—	—	—	—	—
TEPEZZA	0 0.00%	—	—	—	—	—
Neulasta	—	2,293 9.02%	3,221 13.79%	4,475 18.84%	4,534 19.84%	4,648 20.22%
Sensipar Mimpara	—	—	—	—	1,718 7.52%	1,582 6.88%
Epogen	—	—	—	—	1,096 4.80%	1,282 5.58%
Product sales	24,297	24,240	22,204	22,533	21,795	21,892
Revenue	25,979	25,424	23,362	23,747	22,849	22,991

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011
U.S.	26,419 71.89%	23,863 71.39%	19,806 70.26%	18,595 70.64%	18,194 70.03%	18,496 72.75%	17,224 73.73%	18,358 77.31%	18,029 78.90%	18,326 79.71%	17,167 79.25%	15,396 76.74%	14,480 77.53%	13,415 77.70%	11,985 76.92%
ROW	10,332 28.11%	9,561 28.61%	8,384 29.74%	7,728 29.36%	7,785 29.97%	6,928 27.25%	6,138 26.27%	5,389 22.69%	4,820 21.10%	4,665 20.29%	4,495 20.75%	4,667 23.26%	4,196 22.47%	3,850 22.30%	3,597 23.08%
Revenue	36,751	33,424	28,190	26,323	25,979	25,424	23,362	23,747	22,849	22,991	21,662	20,063	18,676	17,265	15,582

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
BLINCYTO volume growth	Q2 FY2026	16.0%	—	—
Nplate volume growth	Q2 FY2026	13.0%	—	—
Otezla volume growth	Q3 FY2025	6.00%	5.00%	—
Repatha volume growth	Q1 FY2026	35.0%	41.0%	—
TAVNEOS volume growth	Q1 FY2026	55.0%	—	—
TEPEZZA volume growth	Q2 FY2026	6.00%	6.00%	—
TEZSPIRE volume growth	Q1 FY2026	32.0%	—	—
Unit volume growth	Q1 FY2026	9.00%	14.0%	—

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023	Q3 FY2023
BLINCYTO volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Nplate volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Otezla volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Repatha volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TAVNEOS volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TEPEZZA volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
TEZSPIRE volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Unit volume growth	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.